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Our immune defense depends on two specialized armed forces. The innate force acts as an alarm mechanism that senses changes
in the microenvironment through the recognition of common microbial patterns by Toll-like receptors (TLR) and NOD proteins.
It rapidly generates an inﬂammatory response aimed at neutralizing the intruder at the mucosal checkpoint. The innate arm also
communicatesthismessagewithmorespecializedadaptiveforcesrepresentedbypathogen-speciﬁcBcellsandTcells.Interestingly,
B cells also express some innate sensors, like TLR7 and TLR9, and may respond to bacterial hypomethylated CpG motifs and
single-stranded RNA viruses. Intracellular nucleic acid sensing TLRs play an important role in the pathogenesis of Systemic
Lupus Erythematosus (SLE). In this review, we describe recent achievements in the development of oligonucleotide—(ODN)-
based inhibitors of TLR9 and/or TLR7 signaling. We categorize these novel therapeutics into Classes G, R, and B based on their
cellular and molecular targets. Several short ODNs have already shown promise as pathway-speciﬁc therapeutics for animal lupus.
We envision their future use in human SLE, microbial DNA-dependent sepsis, and in other autoinﬂammatory diseases.
1. Overview
In this review, we present multiple lines of evidence that
short oligonucleotides (ODN) containing stretches of 3–5
guanine nucleotides may act as TLR9-speciﬁc antagonists.
We deﬁne their optimal sequence requirements, discuss the
importance of secondary structures, present evidence of
their eﬃcacy in animal models of lupus and sepsis in vivo,
and oﬀer a new classiﬁcation based on their mechanisms
of action and cellular selectivity. We further discuss the
ability of phosphorothioate-modiﬁed ODNs to act as TLR7
antagonists.
2. Toll-Like Receptor 9 as an Immune Sensor of
UnmethylatedCpG-DNA
Cellsofourinnate immune systemcanbeactivatedbybacte-
rial DNA, but not by our own DNA [1]. When unmethylated
CpG sequences ﬂanked with two purines at the 5  end and
with two pyrimidines at the 3  end (so-called CpG motif)
were found to be necessary for bacterial DNA-induced
immune activation [2–5], the whole ﬁeld of oligonucleotide
research exploded culminating in the discovery of the TLR9
as a receptor responsible for CpG-ODN (and bacterial DNA)
action [6, 7]. This eﬀect was recently found to be heavily
dependent on DNA sugar backbone recognition by TLR9
[8]. Even though additional DNA recognition molecules and
TLR9-independent pathways were recently discovered [9–
15], TLR9 itself appears to be both necessary and suﬃcient
for observed immunostimulatory eﬀect of CpG-containing
ODNs (reviewed in [3]). Interestingly, TLR9 has relatively
limited distribution and in humans is found exclusively in
TypeIinterferon-producingplasmacytoiddendriticcellsand
in B cells [16]. In mice, macrophages and myeloid dendritic
cells also express high levels of TLR9 and respond to CpG-
ODN stimulation [17, 18].
Toll-like receptors, including TLR9, warn us of the
presence of infection, and the ligand-receptor interaction2 Mediators of Inﬂammation
mobilizes cellular resources to promote an early inﬂam-
matory response and to initiate robust adaptive immune
response. For example, TLR9-activated B cells enter cell cycle
and proliferate, upregulate cell-surface molecules involved
in antigen presentation/collaboration with cognate T cells
(e.g., CD40, MHC Class II and CD86), and secrete multiple
chemokines and proinﬂammatory cytokines (e.g., IL-6 and
TNF-α)( [ 19], reviewedin [3]).B cells also secrete polyclonal
IgM and IgG3 [2, 20] and with the T cell help can undergo
class switching to other Ig isotypes. Once the immediate
danger is neutralized, certain TLR(9)-primed B cells and
dendritic cells start making regulatory cytokines, such as
IL-10 and TGF-β ([20, 21] and Lenert et al., unpublished
observation) limiting the ongoing inﬂammation [21]. In
dendritic cells, TLR9 (and TLR7) activation induces among
others high levels of type I IFN [22], a cytokine heavily
implicated in the pathogenesis of Systemic Lupus Ery-
thematosus and Sj¨ o g r e n ’ ss y n d r o m e[ 23–26]. Thus, innate
activation through TLRs stands at the cross-roads between
innate and adaptive immunity, and if left unchecked may
cause chronic immune stimulation and autoimmunity. For
example, expansion of transgenic rheumatoid factor-speciﬁc
B cells in lupus-prone MRL-Faslpr/lpr mice is directly
dependent on MyD88/TLR expression, but not on T cells
[27]. However, the role of TLR9 in the pathogenesis of
lupus in this strain of mice remains controversial as some
reports suggest that TLR9 may be actually protective rather
than pathogenic via induction of regulatory T cells [28,
29].
In contrast to the LPS receptor TLR4/MD2, TLR9
is not localized on the cell surface but signals from an
interior compartment as ﬁrst discovered by Wagner’s group
[30, 31]. In concord with this observation, CpG-ODN-
but not LPS-induced intracellular signaling is sensitive to
inhibitors of endosomal acidiﬁcation (e.g., chloroquine)
[32]. Cationic peptides such as LL-37 or polymixin may
facilitate the uptake of CpG-DNA (including self-DNA)
into early endosomes [33]. Once CpG-ODN enters cells,
TLR9 undergoes relocation from endoplasmic reticulum to
CpG-ODN-containing endosomes [34]. This travel requires
a help from the UNC93b1 shuttle protein [35, 36], as
mice having a mutation in UNC93b1 fail to respond to
intracellular TLR ligands (TLR3, 7 and 9) [37]. After
reaching endosomes, TLR9 undergoes its ﬁnal proteolytic
cleavage into a functional receptor [38, 39]. TLR9 exists
as a preformed homodimer and CpG-ODN binding pro-
motes its conformational change, bringing the cytoplasmic
TIR-like domains close to each other [40]. This allows
a recruitment of the key adapter protein MyD88 which
initiates a signaling cascade. Following further recruitment
of IRAK1/TRAF6 [41, 42], two major signaling pathways are
initiated: ﬁrst through the MAPK/SAPK pathway resulting
in AP1 nuclear translocation and second causing NF-κB
activation [30, 42, 43], reviewed in [3, 44]. In IFN-α
producing cells, PI3K, IRF5, and IRF7 are also implicated
in CpG-ODN-induced cellular activation [45, 46]. Once
these transcription factors bind to their DNA targets,
rapid induction of early inﬂammatory and survival genes
follows.
3. Discovery of TLR9 Inhibitors
During the course of experiments designed to understand
what makes bacterial DNA, but not mammalian DNA,
immunostimulatory [1, 4], Pisetsky’s group discovered
that synthetic oligonucleotides containing poly-G sequences
could block bacterial DNA-induced activation [47, 48]. The
inhibition was seen at relatively high micromolar concen-
trations and required that inhibitors were made with the
nuclease-resistant phosphorothioate (PS) backbone instead
of the natural phosphodiester (PO) backbone. However,
these eﬀects were not speciﬁc for bacterial DNA-induced
activation, as these ODNs could also block other forms
of immune stimulation [49]. Others have observed that
Poly G-ODNs could suppress tumor cell growth with an
IC(50) at 7 micromoles. The inhibition was due to direct
binding of Poly-G ODNs to STAT3 preventing its nuclear
translocation and interaction with target DNA sequences
[50, 51]. As a consequence, the level of survival genes Bcl-2
and Bcl-XL dropped, promoting apoptotic cell death. Thus,
poly-G ODNs may represent a new class of chemothera-
peutic agents capable of blocking immune activation non-
speciﬁcally and promoting apoptotic cell death in tumor
cells.
Envisioning application of TLR9 ligands as potential
vaccine adjuvants and boosters of antitumor immunity,
Krieg’sgroupnoticedthatcertainCpGsequences,likeCCGG
a n dm e t h y l a t e dC Gs e q u e n c e s[ 52, 53], were not only non-
stimulatory, but inhibitory when added to bacterial DNA-
stimulated cultures [53]. These inhibitory CpG-sequences
were overexpressed in certain strains of adenoviruses (e.g.,
serotype 2, but not serotype 12) [52]. Therefore, a concept
of neutralizing or suppressive CpG-sequences was born
[52].
Ourcontributiontotheﬁeldwastoclarifyexactsequence
requirements for TLR9 inhibition by inhibitory oligonu-
cleotides in mouse and human settings and to study their
mechanism of action both in vitro and in vivo. Contribution
from other groups will also be mentioned and a modiﬁed
classiﬁcation of INH-ODNs will be presented.
We decoded sequence requirements for inhibitory ODN
action in TLR9-activated cells by systematically alter-
ing the shortest active 15-mer stimulatory CpG-ODN
2084 (TCCT GACGTT GAAGT) by mutating one or two
nucleotides at the time [54, 55]. A CpG to GpC ﬂip
created a 100-fold less potent TLR9 agonist compared
to the parental molecule; however, the resulting ODN
had no TLR9 inhibitory activity by itself. Interestingly, a
simple switch from CpG to GpG created an ODN that
was capable of blocking both experimental autoimmune
encephalomyelitis and spontaneous lupus in mice, as shown
by Ho et al. [56, 57]. However, a similar ODN failed to
speciﬁcally block TLR9-induced stimulation in mouse B
cells [55]. Exchanging pyrimidines for guanine nucleotides
at the 3  ﬂank of the CpG motif completely abrogated the
stimulatory activity of the prototypic CpG-ODN, creating
an inhibitor of the TLR9 signaling. On the other hand, a
5  ﬂank change from GACGTT to GGCGTT was tolerated
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when these 3 substitutions were combined in a single
ODN,apowerfulTLR9inhibitor-CpG-ODN2088(TCCTG-
GCGGGGAGT) was generated [58, 59]. CpG-ODN-2088
was not only unable to induce TLR9-dependent activation
by itself, but could block TLR9-ligand-induced activation
at very low nanomolar concentrations. All TLR9-induced
biologic outcomes were completely inhibited not only in
m o u s eBc e l l s[ 59], but also in macrophages and dendritic
cells [54]. There was a potency diﬀerence of 100–1000-
fold between control PS-ODNs and INH-ODNs [59]. At
the signaling level, the earliest steps in NF-κB[ 58]a n d
SAPK/MAPK/AP1 activation were promptly and equally
inhibited [60] suggesting a proximal mechanism of INH-
ODN action, possibly at the level of TLR9 receptor itself
[61].
Further mapping studies in mouse B and non-B cells [54,
55] have established the following rules for TLR9-inhibition:
(1) CpG motif, either methylated or unmethylated, is not
required for inhibition; (2) three consecutive G nucleotides
are necessary for inhibition; (3) 5  e n do fa nO D Ni s
important for both stimulation and inhibition: TCC is
optimal for stimulation, while CC(T) triplet is required
for optimal inhibition; (4) the distance between the 5 
CC(T) and downstream GGG triplet should optimally be
3–5 nucleotides long; (5) the order of 5 CC(T)→GGG-3 
is critical as ODNs with the reverse order, for example,
5 GGG→CC(T)-3 , or with the reverse sequence are non-
inhibitory; (6) the intervening sequence between the CC(T)
and GGG elements contributes minimally to the overall
ODN activity and can accept multiple modiﬁcations. (7) at
the 3  end of an INH-ODN, it is not the primary sequence
but the length that contributes to the activity; (8) speciﬁc
inhibition of TLR9-induced activation does not require
intrachain and/or interchain Hoogsten hydrogen bonding
between adjacent Gs, as deaza-substituted ODNs [59]a n d
linear INH-ODNs incapable of making these bonds are
equally eﬀective TLR9 inhibitors [62].
ODNs containing the canonical mouse inhibitory motif
for TLR9 (e.g., 2088, 2114, and 4024) were also active
in human B cells, B cell lines, pDCs [63, 64], and in
TLR9-transfected HEK cells [65]. However, extending INH-
ODNs for 4-5 bases at the 5  end signiﬁcantly enhanced
their activity for human cells. The activity in human cells
does not depend on the ability of INH-ODN to either
self-aggregate or directly bind to a stimulatory ODN. As
in mouse TLR9-expressing cells, primary base sequence
and backbone determine INH-ODN activity [65]. Even
though TLR9 binds INH-ODNs as well as CpG-ODNs,
the aﬃnity for TLR9 does not correlate with the biologic
activity (Ashman and Lenert, submitted for publication).
Indeed, recent studies have shown that the sugar backbone
2-deoxyribose determines DNA recognition by TLR9, and
base-free deoxyribose homopolymers may act as TLR9
agonists [66]. Phosphorothioate-modiﬁed deoxyribose has
much higher aﬃnity for both TLR7 and 9 compared to PO-
deoxyribose, transforming these molecules into TLR7 and
TLR9 antagonists [66]. Therefore, we hypothesize that some
other molecule, not TLR9, must mediate sequence-speciﬁc
recognition of INH-ODNs (unpublished data and [65]).
4.Concept of ClassR andClassB INH-ODNs:
Less IsSometimes More
For our mapping studies, we initially used INH-ODN-2114
with the following sequence: 5 TCCTGGAGGGGAAGT-3 
([59]; Table 1). This ODN is a very potent TLR9-antagonist
in both human and mouse settings in vitro [54, 59, 65]
as well as in the MRL-Faslpr/lpr strain of lupus in vivo
[67]. The PO variant of this ODN is active against PO-
CpG-ODNs and bacterial DNA in B cells and mouse
macrophages [68]. As PS ODNs bind to TLR9 with much
higher aﬃnity than PO-ODNs [69, 70], not surprisingly,
PO-INH-ODN 2114 is at least 100-fold less potent against
PS-CpG-ligands. Interestingly, a genomics search has shown
that the optimal inhibitory sequence is severalfold more
prevalent in mammalian DNA compared to bacterial E.coli
DNA, suggesting a physiologic relevance of these ﬁndings
[68].OurINH-ODNsandsimilar ODNsdeveloped byStunz
et al., Barrat et al., and Peter et al. have no inhibitory activity
on TLRs 2, 3, 4, 5, and BCR-induced activation when used at
concentrations up to 1 micromol [59, 71, 72]. The eﬀects on
TL7/8 will be discussed below.
Since INH-ODN-2114 can make (some) G4-stacks
as poly-G ODNs [73]( Figure 1), the interpretation of
these results may be complicated by nonspeciﬁc eﬀects
of G4 stacks on immune activation. As a matter of
fact, TLR9-independent eﬀects of ODN-2114 were seen
in the model of intracellular S. typhimurium infection in
TLR9-deﬁcient bone marrow derived macrophages [74].
Therefore, in order to avoid any contribution from G4
aggregates to TLR9 inhibition, we created INH-ODN 4024
(TCCTGGATGGGAAGT) [63]. This ODN contains both
CC(T) and GGG triplets and is as potent as INH-ODNs
2088 and 2114 for CpG-ODN-stimulated mouse B cells
and macrophages [55, 63]. Further truncation of ODN-4024
resultedintheshortestactive12-merINH-ODN4084-Fwith
the sequence 5 CCTGGATGGGAA3  [62].
In order to better understand the role of secondary
structures, for example, ability to make DNA duplexes or
hairpins,weusedINH-ODN4084Fasatemplate.Wecreated
24 mer-ODNs in which the 4084F sequence was either at
the 5  or the 3  end of the molecule, and was followed (or
preceded) by 12 nucleotides complementary to the 4084F,
making a complete palindrome (Table 1, INH-1, INH-4)
[62]. We named these new TLR9-antagonists: Class R INH-
ODNs (where “R” stands for restricted activity, [75]) as they
showed similar inhibitory potency for TLR9-activated IFN-
α producing dendritic cells (and macrophages/macrophage
cell lines) as their linear analogues (Class B, broadly-active,
Table 1, INH-18, INH-13), but were between 10–30-fold less
active in resting mouse splenic (follicular) B cells irrespective
of the outcome tested. These ODNs were also less potent
in human peripheral blood B cells and in B cell lines
[62]. Interestingly, even bigger potency diﬀerence (∼100
fold) was observed when these ODNs were made with the
natural phosphodiester backbone [62]. Similar to complete
palindromes, ODNs having short 5  or 3  overhangs (up to 6
nucleotides long) were less active in B cells when compared
to their linear analogues [62]. The diﬀerence in activity4 Mediators of Inﬂammation
Table 1: Oligonucleotides used in this study.
No. Sequence Class Reference
2088 TCCTGGCGGGGAAGT B/G [58, 59]
2114 TCCTGGAGGGGAAGT B/G [58, 59]
4024 TCCTGGATGGGAAGT B [54, 55]
4084F CCTGGATGGGAA B [62]
INH-1 CCTGGATGGGAATTCCCATCCAGG R [62]
INH-4 TTCCCATCCAGGCCTGGATGGGAA R [62]
INH-13 CTTACCGCTGCACCTGGATGGGAA B [62]
INH-18 CCTGGATGGGAACTTACCGCTGCA B [62]
Poly-G GGGGGGGGGGGGGGGGGGGG G [47]
A151 (telomeric) TTAGGGTTAGGGTTAGGGTTAGGG G [61]
GpG TGACTGTGAAGGTTAGAGATGA B [56]
G-ODN CTCCTATTGGGGGTTTCCTAT B/G [72]
IRS-869 TCCTGGAGGGGTTGT B/G [64]
IRS-661 TGCTTGCAAGCTTGCAAGCA R/TLR7 speciﬁc [71]
IRS-954 TGCTCCTGGAGGGGTTGT B/TLR7/9 speciﬁc [71]
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Figure 1: Class B INH-ODN 2114 can undergo G4-stacking in the
presence of potassium ions. INH-ODN 2114 (1μg) was dissolved
in a buﬀer containing potassium ions at 65 degrees for 10 minutes
and then slowly cooled down to room temperature for 2 hours.
For comparison, the same ODN was dissolved in Tris-EDTA, boiled
for 10 minutes and rapidly cooled on ice. Electrophoretic mobility
on 20% native PAGE gel is shown. Gel was stained with Stains All
overnight.
between Class R and B INH-ODNs in B cells could not be
explained by diﬀerences in the uptake, but could depend on
the ability of these ODNs to reach diﬀerent TLR9-expressing
compartments, for example, early versus late endosomes [62,
76–78].Wehypothesized,thatinBcells,ClassRINH-ODNs,
similar to mammalian DNA, may have restricted access
to late endolysosomes. Interestingly, similar to diﬀerences
between Class R and B INH-ODNs, human na¨ ıve B cells and
resting mouse follicular B cells poorly respond to complex
TLR9 agonists, for example, double-stranded bacterial DNA
and type A(D) CpG-ODNs which have a palindromic center
and G-rich tails [20, 79–81]. Since the signal through the B
cell receptor for antigen allows B cells to respond to a wider
rangeofTLR9ligandsincludingcomplexTLR9-agonists[78,
82–86], we wondered whether the same principal holds true
for Class R TLR9-antagonists. We studied this hypothesis
in both autoimmune and nonautoimmune settings. We
used autoreactive rheumatoid factor-speciﬁc AM14 B cells
as a model for BCR/TLR9 cross talk [87]. AM14 B cells
proliferate upon recognition of DNA/or RNA containing-
immune complexes by their B cell receptor for antigen
only if co-stimulated through the TLR7 or TLR9 [88, 89].
When AM14 B cells were stimulated with linear CpG-
ODN ligands (e.g., with CpG-ODN 1826), similar to non-
autoreactive B cells, Class R INH-ODNs were at least 10-
fold less potent inhibitors compared to Class B INH-ODNs
[62]. However, when DNA-containing immune complexes
were used for stimulation, the potency of Class R INH-
ODN increased for at least 10-fold equalizing that of Class
B INH-ODNs [62]. Since in AM14 B cells, INH-ODNs
fail to inhibit signaling through the BCR, or by LPS, we
concluded that the increased potency of Class R INH-
ODNs for BCR/TLR9 coactivated autoreactive B cells could
be advantageous for selective targeting of autoimmune B
cells in lupus. Indeed, contrary to our expectations, our
in vivo studies in the MRL-Faslpr/lpr strain showed that
potent linear TLR9-speciﬁc antagonist (Class B INH-18) was
surprisingly ineﬀective while treatment with palindromic
Class R INH-1 resulted in improved survival and less renal
pathology [62]. Furthermore, levels of anti-dsDNA and anti-
Sm/RNPantibodiesweresigniﬁcantlyreducedandabnormal
lymphoproliferation was halted. These results could be
explained by the fact that TLR9 may have some protective,
rather than pathogenic, eﬀects in the MRL-Faslpr/lpr strain
of lupus mice. TLR9 may be critical for the induction of
regulatory T cells in this strain as hypothesized by Wu
and Peng [29]. Moreover, the principal cytokine involved
in the pathogenesis of lupus in this strain appears toMediators of Inﬂammation 5
be IFN-γ,n o tI F N - α, as MRL-Faslpr/lpr mice deﬁcient in
IFN-α receptor have more severe disease [90–92]. Other
explanations are also possible, including selective eﬀects of
palindromicINH-ODNsonTLR7activation,asTLR7playsa
well-proven role in the pathogenesis of MRL-Faslpr/lpr lupus
[28].
5. Telomeric TTAGGGRepeatsas Immune
Modulating Agents
OligonucleotidescontainingrepetitiveTTAGGGmotifswere
developed by Klinman’s group and were shown to have
multiple eﬀects on immune activation [61]. TTAGGG
repeats are found in telomeric ends and physiologically
protect mammalian chromosomes from degradation [93].
It appears that when our own DNA is released from
cells, these telomeric regions are responsible for inhibitory
eﬀects of mammalian DNA [53, 61]. Indeed, DNA from
telomerase-deﬁcient mice is much less suppressive than the
control DNA (reviewed in [94]). Synthetic ODNs containing
TTAGGG repeats were capable of blocking the production
of proinﬂammatory and TH1 cytokines induced not only
with TLR9 ligands, but also with a variety of polyclonal
activators and antigens [61, 94, 95]. For example, they
were active against double-stranded RNA, peptidoglycan,
and even against lipopolysaccharide (LPS) when IFN-γ
p r o d u c t i o nw a sm e a s u r e da sa no u t c o m e( r e v i e w e di n
[94]). Interestingly, others have shown that similar G-
rich ODNs can bind IFN-γ directly and act as aptamers
[96]. In vivo, these ODNs showed a remarkable potential
to prevent pathology in animal models of inﬂammatory
arthritis induced by intra-articular injection of CpG-ODNs
[97], spontaneous SLE in NZB/W mice [98], experimental
uveitis [94],acutesilicosis[99],andLPS-inducedtoxicshock
[100]. Interestingly, while TTAGGG-ODNs were capable of
preventing the development of nephritis in NZB/W mice,
treatmentofanimalswithestablishedlupusnephritisdidnot
stop the progression of the disease [98]. Authors concluded
that these ODNs may be promising agents for treatment
of a variety of autoimmune and inﬂammatory diseases,
particularly when administered early in the course of the
disease [94].
While the mechanism of action of these ODNs is incom-
pletely understood, immunosuppressive ability of these
ODNS was found to be heavily dependent on their ability to
make complex structures, for example, G4-stacks. TTAGGG
motifs may act, at least in part, by selectively binding
to STAT1 and STAT4 and by blocking their subsequent
phosphorylation [95, 100]. Interestingly, we were not able
to observe any (inhibitory) eﬀects of linear (non-G4-stack
forming) Class B INH-ODNs on STAT signaling suggesting
thatdiﬀerentclassesofINH-ODNsmayactthroughdiﬀerent
signaling pathways (data not shown). Others have shown
that G-rich ODNs, similar to TTAGGG repeats, can also
target another member of the STAT family, a STAT3 onco-
gene, with an IC(50) of 7 micromol [50, 51]. Other cellular
targets of G-rich ODNs have also been identiﬁed, including
scavenger receptors [73], nucleolin [101], and interestingly, a
lupus autoantigen-Ku [102].
6. Combined TLR7/TLR9 Antagonists
Barrat-Coﬀman’s group at Dynavax used our INH-ODN
2114 [54, 59] as a template for creating novel TLR9
inhibitors, such as IRS 869 (TCCTGGAGGGGTTGT). They
studied their eﬀects in human and mouse B cells and in IFN-
α-producing plasmacytoid dendritic cells [64]. Noticeably,
the ODN variant they used (IRS 869) diﬀered from INH-
ODN 2114 only by two A → T substitutions at the 3 
end where the number of nucleotides, but not the primary
sequence, matters [54, 55]. They found that 4 contiguous G
residues were essential for TLR9 inhibition [64]. Since IRS
869couldmakeG4-stacks,theyalsostudiedthecontribution
of primary sequence versus G4-aggregates to the inhibitory
activity. Similar to our results, they observed that linear
sequence, not the G-aggregate, was responsible for TLR9
inhibition in human B cells [64]. They further showed
that these ODNs were eﬃcacious in vivo in a model of
d-galactosamine + CpG-ODN-induced sepsis. INH-ODNs
prevented massive systemic inﬂammation and cytokine
release responsible for sepsis in this model [64]. This eﬀect
was conﬁrmed in a recent study by Plitas et al. in a model of
polymicrobial sepsis [103].
Barrat’s group subsequently developed short INH-ODNs
that preferentially block TLR7-induced innate activation.
The prototypic TLR7 antagonist IRS 661 contained 5 GC
motifs equally spaced within the complete palindrome
[104]. This ODN speciﬁcally blocked small TLR7/8 agonist
(R848)-induced splenocyte IL-6 secretion, but was ineﬀec-
tive against TLR9-ligand induced activation. In their hands,
TLR9-speciﬁc antagonists (e.g., IRS 869) failed to block
TLR7 (R848)-dependent activation. The same group also
developed IRS 954 (TGCTCCTGGAGGGGTTGT) which
was capable of simultaneously blocking both TLR7- and
TLR9-dependent activations. Combined TLR7 and TLR9
inhibitors suppressed IFN-α induction by either ultraviolet-
light irradiated HSV (DNA), inactivated inﬂuenza virus (ss
RNA virus), or by RNA-containing immune-complexes. IRS
954 also slowed down the progression of spontaneous lupus
in the NZB/W-F1 strain of lupus mice and reduced the
production of multiple autoantibodies (e.g., anti-dsDNA,
antinucleosome, anti-Sm, and anti-RNP antibodies) [104].
Interestingly, the control ODN used in their study lacked the
TLR9 motif but contained the TGC motif which was buried
in the interior of the molecule. Since this control ODN
was apparently ineﬀective, one may wonder which pathway
(TLR7 or 9?) was a primary target of INH-ODNs in this
model [104]. Interestingly, NZB/W-F1 mice, similar to SLE
patients, constitutively express high levels of IFN-α regulated
genes. Moreover, treatment with IFN-α accelerates disease,
while mice deﬁcient in the IFN-α receptor develop less severe
disease with delayed onset [105, 106].
In contrast to the results from Barrat’s group, several
groups, including our own, have shown that PS ODNs
including INH-ODNs (but not PO INH-ODNs) have
backbone-dependent and sequence-independent eﬀects on
TLR7 activation induced by either RNA-containing immune
complexes, or by small TLR7 agonists like R837 and CL075
[57, 62, 89, 107–109]. However, in contrast to RNA-immune6 Mediators of Inﬂammation
Table 2: Classiﬁcation of inhibitory oligonucleotides.
Class Characteristics Prototype TLR9 inhibition
in B cells
TLR9 inhibition in
DC/MΦ
TLR7 inhibition
(backbone eﬀect)
Inhibition of other
signaling pathways
Reference
G G4-stacking TTAGGGn + +++ ++ +++ [61]
R Palindromic, Short 5 
or 3 overhangs
INH-1 + +++ ++ — [62]
B Linear INH-18 +++ +++ ++ — [62]
complex-induced activation of pDCs, R848-induced B cell
activation is relatively diﬃcult to inhibit with TLR9-speciﬁc
antagonists, but remains sensitive to TGC-containing ODNs,
clarifying this controversy (Lenert, unpublished data).
7. Proposed Mechanismsof INH-ODN Action
Diversity of published sequences for TLR9 inhibition sug-
gests a possibility of diﬀerent sites and mechanisms respon-
sible for their inhibitory action. For example, INH-ODNs
may act as nonsequence speciﬁc competitors for receptor-
mediated endocytosis or phagocytosis. This eﬀect may
depend on a cell type, presence of scavenger receptors (e.g.,
CXCL16, SR-A, CD36, MARCO) and on the overall length
of INH-ODNs, as well as on their ability to make G4 stacks
[73,110,111].Ingeneral,longerandG-richODNsarebetter
taken up by macrophages than shorter ODNs. The opposite
is true in B cells [111]. A second possibility is inhibition of
TLR9-traﬃckingorTLR9-processingintofunctionallyactive
product [38]. A third mechanism may involve competitive
antagonism at the level of TLR9-expressing endosome. For
example, INH-ODNs may bind TLR9 and prevent it from
undergoing a conformational change critical for recruit-
ing MyD88 [40]. Further mechanism may include inhibi-
tion of endolysosomal acidiﬁcation (similar to chloroquine
action) or pharmacologic inhibition of various proteases,
for example, cathepsins [112] or asparaginyl endopeptidases.
Recently discovered cysteine protease asparaginyl endopep-
tidase is important for TLR9 processing in DCs, but not
in macrophages [39]. There is also a possibility that certain
INH-ODNs may work downstream of the TLR9 (and TLR7)
for example, at the level of STATs 1, 3, and 4. Finally, while
TLR9-speciﬁcinhibitorsmayblockTLR7-inducedactivation
via their backbone sugars [66], TLR9 itself is not needed for
this inhibition (Ashman et al., unpublished observations).
8.Revised Classiﬁcationof INH-ODNs
A few years ago we proposed a classiﬁcation of INH-ODNs
into two major categories: Class B and Class R [75]. Class B
INH-ODNs are broadly reactive linear ODNs that potently
block CpG-induced activation in all TLR9-expressing cells.
On the other hand, Class R INH-ODNs are capable of
making signiﬁcant secondary structures and are less active
in resting B cells. We initially classiﬁed all complex INH-
ODNs into the Class R category [75]. However, it is now
clear that a substantial diﬀerence exists between telomeric
and palindromic ODNs in terms of their ability to make G4-
stacks and their TLR9-speciﬁcity. Therefore, in this revised
classiﬁcationwedeﬁneanewcategoryofINH-ODNs—Class
G. Class G INH-ODNs contain multiple G3 triplets (like
telomeric repeats) or G4 tetrads and are capable of making
large G-aggregates. They inhibit not only signaling through
the TLR9, but also activation through other TLRs. They are
directly proapoptotic in tumor cells and can additionally
block stimulation of other immune cells, for example, T
cells, nonspeciﬁcally. Table 2 depicts the most important
characteristics of these three categories of TLR9 antagonists.
9. Conclusions
At least three diﬀerent classes of INH-ODNs have recently
been developed. While all these ODNs can block TLR9-
dependent activation, and exhibit backbone-dependent
eﬀects on TLR7 stimulation, depending on their size and
ability to make G4-stacks, they may have additional cellular
targets. For example, telomeric TTAGGG repeats and poly-G
ODNs can be classiﬁed as Class G INH-ODNs. Compared
to other classes they are relatively TLR9-nonspeciﬁc. They
can block phosphorylation and nuclear translocation of
multiple members of the STAT family, for example, STAT
1, 3, and 4. They can additionally interact with scavenger
receptors on macrophages, Ku-autoantigen, and with nucle-
olin. They showed potent immune-modulatory eﬀects in
animal models of lupus in the NZB/W-F1 strain [98], and
in various experimental models of arthritis, sepsis, uveitis,
and silicosis (reviewed in [94]). Because of their cellular
and target promiscuity, they can be more immmunosup-
pressive than other classes of INH-ODNs. Thus, chronic
treatment with Class G INH-ODNs may potentially lead
to enhanced susceptibility to infection, even though the
phenotype of mutated mice including those lacking the
functional transporter molecule UNC93B1 is relatively mild
[37]. Class B INH-ODNs are strictly linear ODNs unable
to make signiﬁcant secondary structures. They require a
5 CC(T)→GGG-3  motif to block TLR9-induced activation
in all responding cells, both in humans and in mice.
Interestingly, they are less protective in the MRL-Faslpr/lpr
strainwhencomparedtoClassRINH-ODNs.Theymayﬁnd
applications for prevention/treatment of TLR9-dependent
microbial sepsis and chronic inﬂammation. When the num-
ber of consecutive Gs in a linear INH-ODN is increased from
3 to 4-5, this increases a chance for G4 stacking and for
nonspeciﬁc eﬀects on immune activation. Finally, Class R
INH-ODNs are longer (20–28mer) ODNs capable of either
dimerizing or making hairpins. This property of Class R
INH-ODNs depends on ODN-concentration, presence of
ions, and on temperature. They are very potent suppressorsMediators of Inﬂammation 7
of TLR9-induced activation in pDCs and macrophages, but
are 10–30-fold less potent in human na¨ ıve B cells and mouse
follicular B cells [62]. This cell selectivity of palindromic
INH-ODNs is independent of the G4-stacking. BCR cross-
linking increases their potency for TLR9-activated B cells for
at least 10-fold making them ideal candidates for targeting
dsDNA-, nucleosome-, or RF-speciﬁc autoreactive B cells.
All three classes of TLR9-antagonists have sequence-
independent backbone-dependent eﬀects on TLR7 (and
possibly TLR3?) stimulation. TGC triplets may additionally
increase the potency of an INH-ODN for the TLR7 pathway
[71]. Literature search shows that classes B and G INH-
ODNs and combined TLR7/9 inhibitors are eﬀective in
animal models of lupus [62, 67, 98, 104, 113]. We envision
their future use as therapeutic agents for human lupus.
Abbreviations
TLR: Toll-like receptor
INH-ODN: Inhibitory oligonucleotide
BCR: B cell receptor for antigen
SLE: Systemic lupus erythematosus.
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